Navigation Links
Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program

SEATTLE, Dec. 16 /PRNewswire/ -- The Washington Life Sciences Discovery Fund (LSDF) has awarded nearly $4.7 million to launch the start-up phase of the Washington Vaccine Alliance (WAVA) and to support initial research into three new vaccines for E. coli, herpes and syphilis. Announced today, the grant is funded by Washington's$350 million tobacco-lawsuit-settlement bonus and provides essential funding to bring this innovative new organization to life.

WAVA core operations during the initial startup phase will operate within the Vaccine and Infectious Disease Institute of Fred Hutchinson Cancer Research Center.

WAVA is a consortium of seven nonprofit-research institutions that is focused on providing the necessary skills and infrastructure to develop, test and deploy new or improved vaccines for many of the world's most challenging diseases. In addition to the Hutchinson Center, the consortium includes Battelle Pacific Northwest Division, Infectious Disease Research Institute (IDRI), PATH, Seattle Biomedical Research Institute (SBRI), University of Washington (UW), and Washington State University (WSU).

"This creative new consortium is a demonstration of the innovation and determination of the members to bring new vaccine solutions to world," said Harlan Patterson, executive director of WAVA.

Scientists at WAVA organizations are collectively researching about a dozen disease clusters that are potential candidates for vaccines and which have succeeded in winning major internationally focused research grants in infectious diseases. The WAVA structure will allow the member organizations to more effectively develop and share critical skills and facilities, help build economic activity for vaccines in Washington, and position the organizations to partner with commercial pharmaceutical and biotech companies in the final vaccine development and deployment stages.

"WAVA represents a chance for the state of Washington to become an international center recognized for both research and vaccine development," said Larry Corey, M.D., principal investigator of the LSDF-funded project and co-director of the Vaccine and Infectious Disease Institute at the Hutchinson Center. "The successful development and deployment of even one vaccine will have a significant impact on the health of the citizens and will provide a very cost-effective intervention to reduce overall health care costs."

The LSDF award provided critical funding to complete the first phases of three new vaccine projects and the ability to secure funding for the rest of the development process. The projects aim to:

-- Develop an E. coli vaccine for cattle (a joint effort of WSU, UW and the University of Idaho). Researchers will test and identify the best candidate for a vaccine that would reduce the level of E. Coli O157 in cattle to a level that would prevent transmission to humans via meat or waste.

-- Develop a herpes vaccine (a joint effort of the Hutchinson Center, IDRI and UW). Researchers will test and select the most effective vaccine formulations for phase 1 clinical trials.

-- Develop a syphilis vaccine (a joint effort of UW, IDRI and the University of Victoria). Researchers will test, evaluate and select the best vaccine formulation to complete preclinical development and then test in phase 1 clinical trials.

Initially, WAVA will create several core service centers that are critical to bring vaccines to market: discovery, development, production and deployment. These services will be extremely cost effective by taking advantage of existing expertise and sharing these resources across the larger portfolio of vaccine projects. Member organizations will contract with each other to speed the testing and development process. The service cores will each have a lead organization and include vaccine economics (PATH), protein expression and purification (SBRI), formulation and early testing (IDRI), proteomics (Battelle), immune monitoring (Hutchinson Center and UW). The Hutchinson Center will also oversee informatics and clinical trials design and management.

"Washington state has accumulated a critical mass of expertise in crucial areas necessary for the successful identification and development of vaccines. The creation of WAVA provides the catalyst to allow each member to create new programs that build upon the substantial existing successes," said King Holmes, M.D., Ph.D., chair of the UW Department of Global Health.

The portfolio of vaccine projects for WAVA covers major infectious diseases that await the development of effective and affordable vaccines. These include HIV, hepatitis C, influenza, diarrheal diseases (especially of infants and children), pneumonia of the elderly, sexually transmitted infections (such as genital herpes, syphilis, and chlamydia), and the pandemic infections of tuberculosis and malaria.

"The worldwide recognition of the potential for vaccines -- increased use of existing, improved and new -- creates the opportunity for the state of Washington to contribute to an unprecedented reduction of the human and financial costs of some of our greatest health challenges," said Chris Elias, M.D., M.P.H., president and CEO of PATH.

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit

About the Life Sciences Discovery Fund

The Life Sciences Discovery Fund, a Washington State agency established in May 2005, makes grant investments in innovative life sciences research to benefit Washington and its citizens. For more information on the Life Sciences Discovery Fund, visit:

     Dean Forbes                    Harlan Patterson (WAVA)
     206-605-0311                   206-434-1164    

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... International Society for Pharmaceutical Engineering (ISPE) ... annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in ... largest number of attendees in more than a decade. , “The 2015 ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... This fall, ... at competitive events in five states to develop and pitch their BIG ideas to ... from each state are competing for votes to win the title of SAP's Teen ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
Breaking Biology Technology:
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):